期刊文献+

B淋巴细胞刺激因子相关生物制剂治疗系统性红斑狼疮的研究进展 被引量:3

下载PDF
导出
摘要 B淋巴细胞刺激因子(Blys)对B细胞的发育增殖具有重要作用,狼疮小鼠及系统性红斑狼疮(SLE)患者体内Blys水平增高,阻断Blys的作用可以使狼疮小鼠的病情缓解,存活时间延长,因此,利用抗Blys单克隆抗体、Blys受体融合蛋白、Blys的抑制性短肽、Blys的免疫抑制重组子、Blys类似物及BAFF受体阻滞剂等Blys相关生物制剂可靶向治疗SLE,但生物靶向疗法治疗自身免疫病尚处在初级阶段,本文对部分生物制剂治疗SLE最新进展作一综述。
出处 《国外医学(内科学分册)》 2006年第12期512-515,547,共5页 Foreign Medical Sciences(Section of Internal Medicine)
基金 深圳市医学重点学科建设资助(深卫科发2005/25)
  • 相关文献

参考文献23

  • 1Shu HB, Hu W, Johnson H.[J].J Leukoe Biol,1999,65(5 ) :680-683.
  • 2Moore PA, Belvedere O, Orr A, et al. [J]. Science, 1999,285 ( 5425 ) : 260-263.
  • 3Schneider P, Mackay F, Steiner V, et al. [J]. J Exp Med, 1999,189 : 1747-1756.
  • 4Mukhopadhyay A, Ni J, Zhai Y, et al. [ J]. J Biol Chem, 1999,274 : 15975-15981.
  • 5Nardelli B, Belvedere O, Roschke V, et al. [J].Blood. 2001,97( 1 ) : 198-204.
  • 6Gross JA, Johnston J, Mudri S, el al. [J]. Nature, 2000,404( 6781 ) :995-999,
  • 7Thompson JS. Bixler SA, Qian F, et al.[J]. J Science, 2001 , 293 ( 5537 ) : 2108-2111.
  • 8Smith KGC, Light A, O'Reilly LA, et al. [J] J Exp Med, 2000,192(3) :475-484.
  • 9Batt M Groom J, Cachero TG, et al. [J]. J Exp Med, 2000,192 ( 10 ) : 1453-1466.
  • 10Laabi Y Strasser A. [J]. Science, 2000,289(5481) :883-884.

同被引文献19

  • 1苏虹,叶冬青(审校).B淋巴细胞刺激因子及其拮抗剂与系统性红斑狼疮[J].国际免疫学杂志,2006,29(3):184-188. 被引量:3
  • 2国家食品药品监督管理局.药物生殖毒性研究技术指导原则[S].2006.
  • 3Christian MS, Laskin OL, Sharper V, et ol. Evaluation of the dvelopmental toxicity of lenalidomide in rabbits [J]. Birth Defects Res (B Dev Reprod Toxicol), 2007, 80 (3): 188-207.
  • 4Zheng Y, Gallucci S, Gaughan JP, etal. A role for B cell-activating factor of the TNF family in chemically induced autoimmunity [J]. J Immunol, 2005, 175 (9): 6163-6168.
  • 5ICH Steering Committee. Harmonised tripartite guideline S5(R2) detection of toxicity to reproduction for medicinal products & toxicity to male fertility [ S ]. 2005.
  • 6Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease [J]. Arthritis Res Ther, 2003, 15 (Suppl 4): 17-21.
  • 7Vallerskog T , Heimburge M , Gunnarsson I, etal. Dif- ferential effects on BAFF and APRIL levels in rituximab- treated patients with systemic lupus erythematosus and rheumatoid arthritis [J]. Arthritis Res Ther, 2006, 8 ( 6) : 167.
  • 8Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. [J]. Nat Rev Immunol, 2006,6(5) :394-403.
  • 9Reynolds JA, Toescu V, Yee CS. Effects of rituximab on resistant SLE disease including lung involvement[J]. Lupus,2009,18(1 ) :67 -73.
  • 10Looney RJ, Anolik JH, Campbell D, etal . B cell deple tion as a novel treatment for systemic lupus erythemato sus: a phase I/II dose-escalation trial of rituximab[J] Arthritis Rheum, 2004,50 (8) : 2580-2589.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部